Demyelinating neuropathy and local toxicity caused by extravasated Brentuximab vedotin

被引：8
|
作者：
Hoffmann, J. C. [1 ]
Soliman, M. [2 ]
Koch, J. C. [2 ]
Liman, J. [2 ]
Schoen, M. P. [1 ]
Mitteldorf, C. [1 ]
机构：
[1] Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany
[2] Univ Med Ctr Gottingen, Dept Neurol, Gottingen, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2020年 / 34卷 / 10期
关键词：
D O I：
10.1111/jdv.16502
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E626 / E628
页数：4
相关论文
共 50 条
  • [21] Optic Neuropathy Caused by Digoxin Toxicity
    Hassanzadeh, Bahareh
    Bhat, Sushanth
    Tohidi, Vahid
    Noor, Emad
    He, Ming
    ANNALS OF NEUROLOGY, 2013, 74 : S36 - S37
  • [22] Increased Rate of Pulmonary Toxicity in Pediatric Patients with Relapsed Hodgkin Lymphoma Receiving Brentuximab Vedotin
    Faulk, Kelly E.
    Sopfe, Jenna
    Pyle, Laura
    Liptzin, Deborah R.
    Liu, Arthur K.
    Franklin, Anna R. K.
    Cost, Carrye R.
    BLOOD, 2017, 130
  • [23] Asymmetric bilateral demyelinating optic neuropathy from tacrolimus toxicity
    Venneti, Sriram
    Moss, Heather E.
    Levin, Marc H.
    Vagefi, M. Reza
    Brozena, Susan C.
    Pruitt, Amy A.
    Mourelatos, Zissimos
    Trojanowski, John Q.
    Galetta, Steven L.
    Balcer, Laura J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 301 (1-2) : 112 - 115
  • [24] Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.
    Diefenbach, Catherine S. Magid
    Hong, Fangxin
    Ambinder, Richard F.
    Cohen, Jonathon Brett
    David, Kevin Andrew
    Advani, Ranjana H.
    Robertson, Michael J.
    Fenske, Timothy S.
    Barta, Stefan K.
    Palmisano, Neal
    Svoboda, Jakub
    Morgan, David S.
    Karmali, Reem
    Kahl, Brad
    Ansell, Stephen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Brentuximab-vedotin/cisplatin/cytarabine/dexamethasoneHaematological toxicity during off-label use: case report
    Reactions Weekly, 2020, 1807 (1) : 46 - 46
  • [26] Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma
    Hochberg, J.
    Basso, J.
    Klejmont, L.
    Flower, A.
    Bortfeld, K.
    Harrison, L.
    Shi, Q.
    Islam, H.
    Gerard, P.
    Voss, S.
    Cairo, M.
    KLINISCHE PADIATRIE, 2020, 232 (02): : 82 - 82
  • [27] Brentuximab vedotin and rituximab with reduced toxicity chemotherapy in children, adolescents and Young adults with newly diagnosed Hodgkin lymphoma
    Hochberg, Jessica C.
    Klejmont, Liana
    Harrison, Lauren
    Flower, Allyson M.
    Shi, Quihu
    Basso, Jaclyn
    Cairo, Mitchell S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 59 - 59
  • [28] Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma
    Hochberg, Jessica C.
    Klejmont, Liana
    Harrison, Lauren
    Flower, Allyson M.
    Shi, Quihu
    Basso, Jaclyn
    Cairo, Mitchell S.
    BLOOD, 2017, 130
  • [29] Serious transplant-related toxicity in patients with Hodgkin's disease previously treated with brentuximab vedotin - a case series
    Engels, J.
    Stern, M.
    Bucher, C.
    Halter, J.
    Heim, D.
    Passweg, J.
    Gerull, S.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S443 - S443
  • [30] Demyelinating neuropathy caused by point mutations in PMP22 gene: Phenotype variability
    Nascimento, A.
    Grazia, S.
    Otez, C.
    Poo, P.
    Polo, A.
    Jimenez-Mallebrera, C.
    Baas, F.
    Galvez, H.
    Iturriaga, C.
    Colomer, J.
    NEUROMUSCULAR DISORDERS, 2012, 22 (9-10) : 868 - 868
12345